Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL092 + nivolumab versus sunitinib in advanced or metastatic non-clear cell renal cell carcinoma
2022-501703-27-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in non-clear cell renal cell carcinoma (nccRCC) comparing XL092 + nivolumab with sunitinib (2 arms). Primary endpoints: Progression-free survival and Objective response rate. Planned start Jul 2023; status: authorised.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on 2022-501703-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501703-27-00.